Phase I/II Study of Gemcitabine plus Vinorelbine in Non-Small Cell Lung Cancer

被引：0
|
作者：
Emilio Esteban
Joaquin Fra
Norberto Corral
Miguel Valle
Juan Carrasco
Marian Sala
Javier Puerta
Enrique Estrada
Isabel Palacio
Jose Maria Vieitez
Jose Maria Buesa
Angel Jimenez Lacave
机构：
[1] Hospital Central de Asturias,Medical Oncology Department
来源：
Investigational New Drugs | 2002年 / 20卷
关键词：
chemotherapy; gemcitabine; NSCLC; phase I/II; vinorelbine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Because gemcitabine andvinorelbine have demonstrated single-agentactivity in non-small cell lung cancer(NSCLC), we conducted this phase I/II studyto determine the maximum tolerated dose(MTD) and activity of these drugs combined.
引用
收藏
页码：73 / 82
页数：9
相关论文
共 50 条
  • [1] Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer
    Esteban, E
    Fra, J
    Corral, N
    Valle, M
    Carrasco, J
    Sala, M
    Puerta, J
    Estrada, E
    Palacio, I
    Vieitez, JM
    Buesa, JM
    Lacave, AJ
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (01) : 73 - 82
  • [2] Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer
    Esteban, E
    Fra, J
    Sala, M
    Carrasco, J
    Corral, N
    Vieitez, JM
    Estrada, E
    Palacio, I
    Buesa, JM
    Lacave, AJ
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (03) : 317 - 326
  • [3] Phase I/II Study of Gemcitabine and Vinorelbine Plus Cisplatin in Non-Small Cell Lung Cancer
    Emilio Esteban
    Joaquín Fra
    Marian Sala
    Juan Carrasco
    Norberto Corral
    José María Vieitez
    Enrique Estrada
    Isabel Palacio
    José Marí Buesa
    Angel J. Lacave
    Investigational New Drugs, 2002, 20 : 317 - 326
  • [4] Phase I II study of CDDP plus vinorelbine plus gemcitabine in non-small cell lung carcinoma (NSCLC).
    Esteban, E
    Fra, J
    Puertas, J
    Sala, MA
    Carrasco, J
    Palacio, I
    Muñiz, I
    Vieitez
    Lacave, AJ
    Buesa, JM
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S62 - S62
  • [5] Phase mi study of Gemcitabine plus vinorelbine in non-small cell lung cancer (NSCLC)
    Puertas, J
    Esteban, E
    Fra, J
    Liano, JLG
    Vieitez, JM
    Estrada, E
    Palacio, I
    Muniz, I
    Buesa, JM
    Lacave, AJ
    ANNALS OF ONCOLOGY, 1998, 9 : 99 - 99
  • [6] Options in advanced non-small cell lung cancer: A review and report on a phase II study of vinorelbine plus gemcitabine
    Lilenbaum, R
    ONCOLOGIST, 2001, 6 : 16 - 19
  • [7] Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
    C Gridelli
    L Frontini
    F Perrone
    C Gallo
    M Gulisano
    S Cigolari
    F Castiglione
    S F Robbiati
    G Gasparini
    G P Ianniello
    A Farris
    M C Locatelli
    R Felletti
    E Piazza
    British Journal of Cancer, 2000, 83 : 707 - 714
  • [8] Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: A phase II study
    Recchia, F
    Lombardo, M
    De Filippis, S
    Rosselli, M
    Rea, S
    ANTICANCER RESEARCH, 2002, 22 (2B) : 1321 - 1328
  • [9] Gemcitabine plus cisplatin in non-small cell lung cancer: A Phase II study
    Sandler, A
    Ansari, R
    McClean, J
    Fisher, W
    Dorr, FA
    Einhorn, LH
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1079 - 1079
  • [10] Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer
    Ando, S
    Suzuki, M
    Iida, T
    Nakajima, T
    Kimura, H
    ONCOLOGY REPORTS, 2005, 14 (03) : 689 - 694
12345